- The Patent Offices in the U.S. and Canada have issued patents covering Intellipharmaceutics International's (OTC:IPCI -1.1%) Paradoxical OverDose Resistance Activating System (PODRAS) technology, specifically, "Compositions and Methods for Reducing Overdose."
- PODRAS is designed to prevent overdose when more pills than prescribed are swallowed intact.
- Last month, the company filed a U.S. marketing application with the FDA seeking approval of an abuse-deterrent formulation of oxycodone called Rexista. It intends to incorporate PODRAS in an alternate Rexista product.